021-51111890
购物车（）
sales@molnova.cn
LY3372689
CAS No. 2241514-56-5
LY3372689 ( —— )
产品货号. M35580 CAS No. 2241514-56-5
LY3372689 (Formulaic Ia) 是一种具有口服活性的 O-GlcNAcase (OGA) 酶抑制剂。LY3372689 可用于 tau 蛋白病研究，包括阿尔茨海默病。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥1292 | 有现货 |
|
| 5MG | ￥1995 | 有现货 |
|
| 10MG | ￥3004 | 有现货 |
|
| 25MG | ￥5224 | 有现货 |
|
| 50MG | ￥7703 | 有现货 |
|
| 100MG | ￥11399 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称LY3372689
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述LY3372689 (Formulaic Ia) 是一种具有口服活性的 O-GlcNAcase (OGA) 酶抑制剂。LY3372689 可用于 tau 蛋白病研究，包括阿尔茨海默病。
-
产品描述LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer’s disease.
-
体外实验——
-
体内实验LY3372689 shows a dose-dependent change in OGA enzyme occu-pancy (EO) following a single oral dose with a maximum EO of greater than 90% in rat.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Microtubule Associated
-
研究领域——
-
适应症——
化学信息
-
CAS Number2241514-56-5
-
分子量383.44
-
分子式C16H22FN5O3S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 250 mg/mL (651.99 mM; 超声助溶 )
-
SMILESC[C@H]1C[C@H](CCN1Cc1sc(NC(C)=O)nc1F)OCc1noc(C)n1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Sergey Shcherbinin, et al. Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: Translation from rat to human. Alzheimer's & Dementia. 07 December 2020 .
产品手册
关联产品
-
Exoticin
Exoticin shows antinociceptive and neuropharmacological activities, it could be considered as a suitable candidate for the development of analgesic and anxiolytic agents.
-
Experimental Allergi...
Experimental allergic encephalitogenic peptide (human) 是一种 EAE 多肽。Experimental allergic encephalitogenic peptide (human) 诱导豚鼠脑脊髓炎。
-
(+)-Afzelechin
(+)-Afzelechin has a neuroprotective effect on the glutamate-induced neurotoxicity in HT22 cells, it has ABTS cation radical scavenging effects with IC50 values of 23.7 microM.
